PACS Links
What is PACS?
What is a Field Reimbursement Specialist?
PACS reviews
Why certify?
PACS price
PACS recertification
PACS extension
PACS FAQs
Quick contact
info@acmainfo.org

Jul 31, 2026
4 minutes read
You’ve probably seen Ozempic or Wegovy ads all over your TikTok FYP, featured in podcasts, and even in your subway commute. What many patients do not see is the $1,000+ monthly price tag that can come without insurance coverage.1
Often referred to as the “miracle drug”, clinical studies have shown that these medications successfully reduce body weight in patients by 15%-25% on average, after about 1 year.2 Although these drugs have been proven to be highly beneficial for individuals struggling with weight loss, many patients face significant challenges with insurance coverage, making access difficult and/or inconsistent.
GLP-1s can be covered by insurance plans; however, eligibility criteria are complex and often leave patients confused. Medication insurance coverage is often dependent on the condition the drug is prescribed for. GLP-1 drugs specifically are covered by many insurances, including (Medicare Part D, for conditions such as Type 2 diabetes and cardiovascular disease (CVD).3 However, drugs prescribed for weight management are often not included on insurance plans. The Medicare Modernization Act of 2003 prohibits covering drugs used specifically for weight loss.3 This law was established because, at the time, anti-obesity medications were associated with long-term safety and effectiveness concerns. Additionally, weight loss management is considered a “cosmetic” treatment and is not deemed medically necessary.4 As a result, Medicare Part D excludes coverage for medications used solely for weight management. Similarly, many private insurance companies deem weight-loss treatment to be a lower priority and therefore do not include anti-obesity medications in their coverage plans.
So what can you do as a patient to improve your chances at coverage? There are many options you can explore to navigate insurance barriers and ensure access to these medications.
Speak to your doctor to verify the condition your GLP-1 was prescribed for. As mentioned earlier, GLP-1s are commonly covered for CVD and type 2 diabetes. Ensure that all proper documentation is submitted by your provider to support insurance coverage. If your condition is not included under your plan’s benefits, do not be discouraged, as there are still alternative resources available.
Patient assistance programs (PAPs), are offered by manufacturers to help eligible patients obtain medications at a reduced cost or free of charge.5 These programs may require you to submit documentation of insurance denial and also require your healthcare provider to submit additional forms as well. It is important to carefully read all eligibility requirements and work closely with your healthcare provider throughout the application process.

Jul 31, 2026
4 minutes read
You’ve probably seen Ozempic or Wegovy ads all over your TikTok FYP, featured in podcasts, and even in your subway commute. What many patients do not see is the $1,000+ monthly price tag that can come without insurance coverage.1
Often referred to as the “miracle drug”, clinical studies have shown that these medications successfully reduce body weight in patients by 15%-25% on average, after about 1 year.2 Although these drugs have been proven to be highly beneficial for individuals struggling with weight loss, many patients face significant challenges with insurance coverage, making access difficult and/or inconsistent.
GLP-1s can be covered by insurance plans; however, eligibility criteria are complex and often leave patients confused. Medication insurance coverage is often dependent on the condition the drug is prescribed for. GLP-1 drugs specifically are covered by many insurances, including (Medicare Part D, for conditions such as Type 2 diabetes and cardiovascular disease (CVD).3 However, drugs prescribed for weight management are often not included on insurance plans. The Medicare Modernization Act of 2003 prohibits covering drugs used specifically for weight loss.3 This law was established because, at the time, anti-obesity medications were associated with long-term safety and effectiveness concerns. Additionally, weight loss management is considered a “cosmetic” treatment and is not deemed medically necessary.4 As a result, Medicare Part D excludes coverage for medications used solely for weight management. Similarly, many private insurance companies deem weight-loss treatment to be a lower priority and therefore do not include anti-obesity medications in their coverage plans.
So what can you do as a patient to improve your chances at coverage? There are many options you can explore to navigate insurance barriers and ensure access to these medications.
Speak to your doctor to verify the condition your GLP-1 was prescribed for. As mentioned earlier, GLP-1s are commonly covered for CVD and type 2 diabetes. Ensure that all proper documentation is submitted by your provider to support insurance coverage. If your condition is not included under your plan’s benefits, do not be discouraged, as there are still alternative resources available.
Patient assistance programs (PAPs), are offered by manufacturers to help eligible patients obtain medications at a reduced cost or free of charge.5 These programs may require you to submit documentation of insurance denial and also require your healthcare provider to submit additional forms as well. It is important to carefully read all eligibility requirements and work closely with your healthcare provider throughout the application process.
Unlike the PAPs, which are provided by drug manufacturers, prescription savings cards, also known as discount cards, are provided by third-party companies such as SingleCare and are used at pharmacy counters. These cards are used similarly to coupons, and allow patients to pay a discounted, out of pocket price for their medication. These cards are not typically used simultaneously with insurances, but allow many patients access to a reduced cost, as they do not have strict eligibility requirements. Discount cards can be obtained through third-party company websites or by asking the pharmacist or pharmacy staff whether any savings programs are available at the time of purchase.6
Novo Nordisk. Explaining the list price of Wegovy®. NovoCare. Accessed June 12, 2026. https://www.novocare.com/mash/resources/explaining-list-price.html
Zhou Y, Wang X, Li Z, et al. Efficacy and safety of GLP-1 receptor agonists for weight loss: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2025;16:11940170. Accessed June 11, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC11940170/
Congressional Research Service. Medicare Coverage of Anti-Obesity Medications. IF12758. Published April 5, 2024. Accessed June 11, 2026. https://www.congress.gov/crs-product/IF12758
Kyle TK, Dhruva SS, Krumholz HM. Medicare and antiobesity medications: current status and future considerations. JAMA Health Forum. 2024;5(2). Accessed June 12, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC10853087/
Novo Nordisk. Novo Nordisk Patient Assistance Program (PAP). NovoCare. Accessed June 12, 2026. https://www.novocare.com/diabetes/help-with-costs/pap.html
SingleCare. How SingleCare works. Accessed June 13, 2026. https://www.singlecare.com/how-it-works
Unlike the PAPs, which are provided by drug manufacturers, prescription savings cards, also known as discount cards, are provided by third-party companies such as SingleCare and are used at pharmacy counters. These cards are used similarly to coupons, and allow patients to pay a discounted, out of pocket price for their medication. These cards are not typically used simultaneously with insurances, but allow many patients access to a reduced cost, as they do not have strict eligibility requirements. Discount cards can be obtained through third-party company websites or by asking the pharmacist or pharmacy staff whether any savings programs are available at the time of purchase.6
Novo Nordisk. Explaining the list price of Wegovy®. NovoCare. Accessed June 12, 2026. https://www.novocare.com/mash/resources/explaining-list-price.html
Zhou Y, Wang X, Li Z, et al. Efficacy and safety of GLP-1 receptor agonists for weight loss: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2025;16:11940170. Accessed June 11, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC11940170/
Congressional Research Service. Medicare Coverage of Anti-Obesity Medications. IF12758. Published April 5, 2024. Accessed June 11, 2026. https://www.congress.gov/crs-product/IF12758
Kyle TK, Dhruva SS, Krumholz HM. Medicare and antiobesity medications: current status and future considerations. JAMA Health Forum. 2024;5(2). Accessed June 12, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC10853087/
Novo Nordisk. Novo Nordisk Patient Assistance Program (PAP). NovoCare. Accessed June 12, 2026. https://www.novocare.com/diabetes/help-with-costs/pap.html
SingleCare. How SingleCare works. Accessed June 13, 2026. https://www.singlecare.com/how-it-works